[穿越迷宫迈向目标：多柔比星/曲贝替定治疗转移性及初治不可切除平滑肌肉瘤] - Suppr

Suppr

超能文献

[Through the labyrinth towards the goal: doxorubicin/trabectedin in metastatic and initially unresectable leiomyosarcoma].

作者信息

Grabenbauer Felix, Semrau Sabine

机构信息

Strahlenklinik, Universitätsklinikum Erlangen, Universitätsstr. 27, 91054, Erlangen, Deutschland.

出版信息

Strahlenther Onkol. 2025 Jan;201(1):82-84. doi: 10.1007/s00066-024-02324-5. Epub 2024 Nov 28.

DOI:10.1007/s00066-024-02324-5

PMID:39609268

Abstract

摘要

相似文献

[Through the labyrinth towards the goal: doxorubicin/trabectedin in metastatic and initially unresectable leiomyosarcoma].[穿越迷宫迈向目标：多柔比星/曲贝替定治疗转移性及初治不可切除平滑肌肉瘤]

Strahlenther Onkol. 2025 Jan;201(1):82-84. doi: 10.1007/s00066-024-02324-5. Epub 2024 Nov 28.

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.多柔比星单药与多柔比星联合曲贝替定序贯曲贝替定单药一线治疗转移性或不可切除平滑肌肉瘤（LMS-04）：一项随机、多中心、开放标签 3 期临床试验。

Lancet Oncol. 2022 Aug;23(8):1044-1054. doi: 10.1016/S1470-2045(22)00380-1. Epub 2022 Jul 11.

Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.多柔比星联合曲贝替定治疗平滑肌肉瘤：曲贝替定维持治疗

N Engl J Med. 2024 Sep 5;391(9):789-799. doi: 10.1056/NEJMoa2403394.

Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma.多柔比星联合曲贝替定治疗转移性或不可切除的平滑肌肉瘤

Lancet Oncol. 2022 Oct;23(10):e444. doi: 10.1016/S1470-2045(22)00547-2.

Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma.多柔比星联合曲贝替定治疗转移性或不可切除性平滑肌肉瘤

Lancet Oncol. 2022 Oct;23(10):e443. doi: 10.1016/S1470-2045(22)00574-5.

Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma.多柔比星联合曲贝替定治疗转移性或不可切除的平滑肌肉瘤

Lancet Oncol. 2022 Oct;23(10):e442. doi: 10.1016/S1470-2045(22)00546-0.

Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma - Authors' reply.多柔比星联合曲贝替定治疗转移性或不可切除平滑肌肉瘤——作者回复

Lancet Oncol. 2022 Oct;23(10):e445. doi: 10.1016/S1470-2045(22)00563-0.

Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.曲贝替定联合多柔比星治疗晚期子宫或软组织平滑肌肉瘤（LMS-02）：一项非随机、多中心、2 期临床试验。

Lancet Oncol. 2015 Apr;16(4):457-64. doi: 10.1016/S1470-2045(15)70070-7. Epub 2015 Mar 18.

Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature.多柔比星脂质体治疗难治性晚期软组织肉瘤的疗效观察

Oncol Res. 2013;20(10):483-90. doi: 10.3727/096504013x13685487925130.

Doxorubicin and trabectedin for recurrent leiomyosarcoma - A case report.多柔比星与曲贝替定治疗复发性平滑肌肉瘤——病例报告

Gynecol Oncol Rep. 2024 Sep 1;55:101497. doi: 10.1016/j.gore.2024.101497. eCollection 2024 Oct.

本文引用的文献

Unraveling the role of local ablative therapies for patients with metastatic soft tissue sarcoma - A retrospective multicenter study of the Bavarian university hospitals.剖析局部消融治疗转移性软组织肉瘤患者的作用-巴伐利亚大学附属医院的回顾性多中心研究。

Eur J Surg Oncol. 2024 Dec;50(12):108619. doi: 10.1016/j.ejso.2024.108619. Epub 2024 Aug 23.

Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.多柔比星联合曲贝替定治疗平滑肌肉瘤：曲贝替定维持治疗

N Engl J Med. 2024 Sep 5;391(9):789-799. doi: 10.1056/NEJMoa2403394.

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.多柔比星加达卡巴嗪、多柔比星加异环磷酰胺或多柔比星单独作为晚期平滑肌肉瘤的一线治疗：来自欧洲癌症研究与治疗组织软组织和骨肉瘤组的倾向评分匹配分析。

Cancer. 2020 Jun 1;126(11):2637-2647. doi: 10.1002/cncr.32795. Epub 2020 Mar 4.

Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups.曲贝替定与放疗治疗软组织肉瘤（TRASTS）：西班牙（GEIS）、意大利（ISG）、法国（FSG）肉瘤研究组关于黏液样脂肪肉瘤的I期研究结果

EClinicalMedicine. 2019 Mar 11;9:35-43. doi: 10.1016/j.eclinm.2019.03.007. eCollection 2019 Mar.

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.吉西他滨与多西他赛对比阿霉素作为既往未治疗的晚期不可切除或转移性软组织肉瘤一线治疗的疗效（GeDDiS）：一项随机对照3期试验

Lancet Oncol. 2017 Oct;18(10):1397-1410. doi: 10.1016/S1470-2045(17)30622-8. Epub 2017 Sep 4.

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.曲贝替定或达卡巴嗪用于常规化疗失败后的转移性脂肪肉瘤或平滑肌肉瘤的疗效和安全性：一项III期随机多中心临床试验的结果

J Clin Oncol. 2016 Mar 10;34(8):786-93. doi: 10.1200/JCO.2015.62.4734. Epub 2015 Sep 14.

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.多柔比星单药与强化多柔比星联合异环磷酰胺一线治疗晚期或转移性软组织肉瘤的随机对照 3 期试验。

Lancet Oncol. 2014 Apr;15(4):415-23. doi: 10.1016/S1470-2045(14)70063-4. Epub 2014 Mar 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验